Trial Profile
A phase 3, open-label, randomized, allopurinol-controlled study to assess the long-term safety of oral febuxostat in subjects with gout.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Febuxostat (Primary) ; Allopurinol
- Indications Gout
- Focus Registrational; Therapeutic Use
- Acronyms EXCEL
- 18 Nov 2008 Checked against ClinicalTrials.gov record.
- 03 Sep 2008 Sponsor/affilliate changed from TAP Pharmaceuticals to Takeda Global Research and Development Centre as reported in ClinicalTrials.gov record.
- 04 Oct 2007 Status changed from in progress to completed.